Compare TXG & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXG | SRRK |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 6.8B |
| IPO Year | 2019 | 2018 |
| Metric | TXG | SRRK |
|---|---|---|
| Price | $76.37 | $46.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | $20.25 | ★ $56.17 |
| AVG Volume (30 Days) | ★ 2.6M | 1.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 76.97 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $245,893,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.33 | $534.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 68.06 | N/A |
| 52 Week Low | $11.17 | $27.07 |
| 52 Week High | $79.94 | $61.76 |
| Indicator | TXG | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 72.02 | 30.44 |
| Support Level | $56.98 | $45.81 |
| Resistance Level | N/A | $48.23 |
| Average True Range (ATR) | 4.03 | 2.65 |
| MACD | 0.68 | -1.24 |
| Stochastic Oscillator | 80.46 | 4.87 |
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.